🏛️ Verified NIH Record • Updated 2026-06-19

Study of BHV-1400 in IgA Nephropathy (NCT07054684)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Biohaven Therapeutics Ltd.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Who can join: Review the eligibility criteria below.

Location: Site-001 — Farmington, Connecticut

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (15 Sites)

  • Site-001 — Farmington, Connecticut
  • Site-003 — Miami Lakes, Florida
  • Site-011 — Miami Lakes, Florida
  • Site-013 — Orlando, Florida
  • Site-005 — Pembroke Pines, Florida
  • Site-008 — Lawrenceville, Georgia
  • Site-009 — Hinsdale, Illinois
  • Site-012 — Indianapolis, Indiana
  • Site-015 — Shelby, Michigan
  • Site-006 — Chesterfield, Missouri
  • Site-002 — Dakota Dunes, South Dakota
  • Site-014 — Houston, Texas
  • Site-004 — Houston, Texas
  • Site-016 — Salt Lake City, Utah
  • Site-007 — Leicester,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗